Atomoxetine hydrochloride
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2002
- First approval year
- 2002
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Atomoxetine hydrochloride
- Molecular weight
- 291.82
- Structure (SMILES)
- CNCC[C@@H](Oc1ccccc1C)c1ccccc1.Cl
- atomoxetine hydrochloride
- Atomoxetine hydrochloride
- strattera
- Strattera
- (r)-(-)-tomoxetine hydrochloride
- atomoxetin strattera
- Atomoxetine (as hydrochloride)
- atomoxetine as hydrochloride
- atomoxetine hcl
- Atomoxetine hcl
- Atomoxetine HCL [VANDF]
- atomoxetine hcl vandf
- atomoxetine hydrochloride
- Atomoxetine hydrochloride
- Atomoxetine hydrochloride [EP MONOGRAPH]
- Atomoxetine hydrochloride [JAN]
- Atomoxetine hydrochloride [MART.]
- Atomoxetine hydrochloride [MI]
- Atomoxetine hydrochloride [ORANGE BOOK]
- Atomoxetine hydrochloride [USAN]
- Atomoxetine hydrochloride [USP MONOGRAPH]
- Atomoxetine hydrochloride [USP-RS]
- Atomoxetine hydrochloride [WHO-DD]
- atomoxetine hydrochloride ep monograph
- atomoxetine hydrochloride jan
- atomoxetine hydrochloride mart
- atomoxetine hydrochloride mi
- atomoxetine hydrochloride orange book
- atomoxetine hydrochloride usan
And 18 more, listed on the interactive page.
- CAS registry numbers
- 82248-59-7
- ChEMBL ID
- CHEMBL1702
- InChIKey
- LUCXVPAZUDVVBT-UNTBIKODSA-N
- RxNorm IDs (RxCUI)
- 353103
- FDA ingredient codes (UNII)
- 57WVB6I2W0
- 54840
- 11426336
- 45108252
- Applicant
- LILLY
- Approval date
- 26 Nov 2002
- Application number
- NDA021411
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- atomoxetine
- Type
- Synthetic organic
- Drug name stem
- -oxetine
Administration routes
- Oral
- Action type
- Inhibitor
- Target
- DAT
- Gene symbol
- DAT
- Action type
- Inhibitor
- Target
- SERT
- Gene symbol
- SERT
- Mechanism
- Norepinephrine transporter inhibitor
- Action type
- Inhibitor
- Target
- Sodium-dependent noradrenaline transporter
- Protein identifier
- P23975
Open Targets mechanisms
- Mechanism
- Norepinephrine transporter inhibitor
- Action type
- Inhibitor
- Target
- Sodium-dependent noradrenaline transporter
- Condition
- Attention Deficit Disorder with Hyperactivity
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003888
- Subject identifier
- D001289
- Condition
- Sleep Apnea, Obstructive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003918
- Subject identifier
- D020181
- Condition
- Attention Deficit and Disruptive Behavior Disorders
- Highest recorded phase
- 3
- Condition identifier
- HP:0010865
- Subject identifier
- D019958
- Condition
- Syncope, Vasovagal
- Highest recorded phase
- 3
- Condition identifier
- HP:0012668
- Subject identifier
- D019462
- Condition
- Alzheimer Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition identifier
- EFO_0003888
- Condition identifier
- EFO_0003918
- Highest recorded phase
- 2
- Condition identifier
- HP_0010865
- Highest recorded phase
- 3
- Condition identifier
- HP_0012668
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004975
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0007739
- Condition identifier
- MONDO_0007739
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0007743
- Highest recorded phase
- 4
- Warning
- Black Box Warning
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Warning
- Black Box Warning
- Country
- United States
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Event
- abnormal behaviour
- Reports
- 222
- Reporting signal score
- 401.665
- Event
- aggression
- Reports
- 318
- Reporting signal score
- 611.011
- Event
- agitation
- Reports
- 187
- Reporting signal score
- 188.274
- Event
- alanine aminotransferase increased
- Reports
- 175
- Reporting signal score
- 142.275
- Event
- anger
- Reports
- 132
- Reporting signal score
- 239.905
- Event
- anorexia
- Reports
- 58
- Reporting signal score
- 83.1282
- Event
- anxiety
- Reports
- 217
- Reporting signal score
- 107.693
- Event
- aspartate aminotransferase increased
- Reports
- 158
- Reporting signal score
- 130.307
- Event
- attention deficit/hyperactivity disorder
- Reports
- 39
- Reporting signal score
- 94.4847
- Event
- blood alkaline phosphatase increased
- Reports
- 78
- Reporting signal score
- 70.7765
- Event
- convulsion
- Reports
- 146
- Reporting signal score
- 114.865
- Event
- crying
- Reports
- 120
- Reporting signal score
- 204.535
- Event
- decreased eye contact
- Reports
- 24
- Reporting signal score
- 101.005
- Event
- depressed mood
- Reports
- 94
- Reporting signal score
- 103.12
- Event
- depression
- Reports
- 211
- Reporting signal score
- 102.804
- Event
- diarrhoea
- Reports
- 41
- Reporting signal score
- 106.252
- Event
- disturbance in attention
- Reports
- 113
- Reporting signal score
- 134.002
- Event
- drug screen positive
- Reports
- 53
- Reporting signal score
- 111.776
- Event
- dystonia
- Reports
- 60
- Reporting signal score
- 75.0851
- Event
- educational problem
- Reports
- 28
- Reporting signal score
- 88.714
- Event
- ejaculation disorder
- Reports
- 39
- Reporting signal score
- 120.033
- Event
- electrocardiogram qt corrected interval prolonged
- Reports
- 29
- Reporting signal score
- 84.5358
- Event
- grand mal convulsion
- Reports
- 59
- Reporting signal score
- 83.5108
- Event
- hallucination, auditory
- Reports
- 63
- Reporting signal score
- 88.1533
- Event
- heart rate increased
- Reports
- 138
- Reporting signal score
- 129.823
And 21 more, listed on the interactive page.
- NCT00190736
- NCT00190775
- NCT00190879
- NCT00190931
- NCT00191386
- NCT00191659
- NCT00191698
- NCT00191945
- NCT00216918
- NCT00218322
- NCT00485407
- NCT00485459
- NCT00485550
- NCT00485628
- NCT00485849
- NCT00485875
- NCT00486083
- NCT00486122
- NCT00506727
- NCT00510276
- NCT00557960
- NCT00568685
- NCT00700427
- NCT01106430
- NCT01244490
And 5 more, listed on the interactive page.
- Dose
- 0.5 mg/kg/day to 1.2 mg/kg/day, up to 100 mg/day
- Route
- Oral
- How often
- Once daily or twice daily
- Take with or without food
- Use supplied syringe and bottle adapter
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 1
- Polar surface area
- 21.26
- Calculated partition coefficient (ALogP)
- 3.72
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 20
- Molecular formula
- C17H22ClNO
- Monoisotopic mass
- 291.1389920
- Natural product
- No
- 0002-3227
- 0002-3228
- 0002-3229
- 0002-3238
- 0002-3239
- 0002-3250
- 0002-3251
- 0093-3542
- 0093-3543
- 0093-3544
- 0093-3545
- 0093-3546
- 0093-3547
- 0093-3548
- 0904-6908
- 16714-755
- 16714-756
- 16714-757
- 16714-758
- 16714-759
- 16714-760
- 16714-761
- 30698-456
- 31722-714
- 31722-715
And 112 more, listed on the interactive page.
- Recorded assays
- 1,014
- Active assays
- 32
- Confirmatory
- Other
- Screening
- Summary
- Adrenergic Uptake Inhibitors
Related records
Trials (185)
- A Bioequivalence (BE) Study in Healthy Subjects
- A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia
- A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
- A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults
- A Dose Response Effect of Atomoxetine to the Acute Effects of Alcohol
- A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment
- A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder
- A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
- A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- A Novel Pharmacological Therapy for Obstructive Sleep Apnea
- A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
- A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
- A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
- A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
- A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
- A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
- A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
- A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
Approved for (1)
- Attention deficit-hyperactivity disorder
In development for (3)
- Alzheimer disease Phase 2
- Obstructive sleep apnea syndrome Phase 2
- Oppositional defiant disorder Phase 3
Other linked conditions (1)
Targets (1)
- SLC6A2 Norepinephrine transporter inhibitor